+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Insulin Market - Focus on Insulin Delivery Devices [By Devices - Vials & Syringes, Insulin Pens, Insulin Pumps, Insulin Jet Injectors; By Region - North America (The US), Europe (The UK, Germany, France & Italy) and Asia Pacific (Japan, China & India) - Outlook 2025]

  • ID: 5026251
  • Report
  • May 2020
  • Region: Global, China, North America, United Kingdom, United States, Europe, Germany, India, Asia Pacific, France, Italy, Japan
  • 153 pages
  • Rockville Research
1 of 3

FEATURED COMPANIES

  • Beckton Dickinson
  • Eli Lilly & Company
  • Merck & Co.
  • Novo Nordisk
  • Sanofi Aventis
  • MORE

Industry Insights

According to this report, the global insulin market is estimated to be valued at US$ 60 billion in the year 2025, growing at a CAGR of 8% in the period 2019 to 2025. Growth of the market is driven by factors such as prevalence of diabetes cases, ageing population and growing obese population.

Insulin is a peptide hormone produced by beta cells of the pancreas. It is mainly associated with regulation of metabolism of carbohydrates, fats and protein by promoting the absorption of glucose from the blood and protein synthesis. It is mainly administered through subcutaneous injection using various insulin delivery devices such as Vials & Syringes, Insulin Pens, Insulin Pumps and Insulin Jet Injectors.

Insulin market has witnessed many firsts in the year 2019. This includes advent of first glucagon-like peptide (GLP-1) Rybelsus oral tablets. Secondly, FDA has also approved world’s first Artificial Pancreas developed by UVA.

Report Scope

This report “Global Insulin Market - Focus on Insulin Delivery Devices [By Devices - Vials & Syringes, Insulin Pens, Insulin Pumps, Insulin Jet Injectors; By Region - North America (The US), Europe (The UK, Germany, France & Italy) and Asia Pacific (Japan, China & India) - Outlook 2025]” provides a detailed analysis of the global insulin and insulin delivery devices market from qualitative and quantitative outlooks during the forecast period across various classes. It also provides coverage on market dynamics with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.

Parameter Description

  • Base year: 2014
  • Forecast period: 2020 - 2025
  • Market sizing Revenue in US$ Billions & CAGR for the period 2014 to 2025
  • Country coverage: The US, The UK, Germany, France, Italy, China, India & Japan
  • Vendor scope Novo Nordisk, Sanofi Aventis, Eli Lilly & Company, Merck & Co., Beckton Dickinson
  • Report coverage Revenue forecast, market share analysis, company analysis, competitive landscape, market growth drivers, market restraints, market trends and company profiles

Segments Covered

The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, the publisher has segmented the global insulin market report has been segmented on the basis of delivery device classes and region:

Delivery Device Outlook, Revenue (2017 - 2025E, US$ Billions)

  • Vials & Syringes
  • Insulin Pens
  • Insulin Pumps
  • Insulin Jet Injectors

Regional Outlook, Revenue (2017 - 2025E, US$ Billions)

  • North America
  • Europe
  • Asia Pacific

Country Outlook, Revenue (2017 - 2025E, US$ Billions)

  • The US
  • The UK
  • Germany
  • France
  • Italy
  • Japan
  • China
  • India

Vendors Outlook, Revenue (2013 - 2022E, US$ Billions)

  • Novo Nordisk
  • Sanofi Aventis
  • Merck & Co.
  • Beckton Dickinson
  • Eli Lilly & Company

Target Audience

  • Insulin Drug Manufacturers
  • Chemical Suppliers
  • Delivery Device Manufacturers
  • End Users
  • Research Professionals
  • Healthcare Consultancies
  • Regulatory Bodies

Key questions answered in the report

  • Historical market size of insulin and insulin delivery devices from 2014 to 2019 in US$ Billions.
  • Projected market growth in the forecasted period 2020 to 2025 with estimated revenue for each year in US$ Billions.
  • Revenue forecasts of major insulin delivery devices in the period 2014 to 2025 in US$ Billions.
  • Regional and country analysis of insulin and insulin delivery devices is provided for the period 2014 to 2025 in US$ Billions.
  • Market drivers, restraints and industry trends that has impact on revenue.
  • Profiling of major companies with detailed analysis of major insulin drugs approved for marketing as well as in pipeline.

Customization

The publisher provides customization of the study in order to provide specific information as sought by the client.

Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Beckton Dickinson
  • Eli Lilly & Company
  • Merck & Co.
  • Novo Nordisk
  • Sanofi Aventis
  • MORE
1. Executive Summary

2. Research Methodology

3. Diabetes
3.1 Overview
3.2 Types of Diabetes
3.3 Diabetes Management

4. Insulin
4.1 Overview
4.2 Types of Insulin
4.3 Market Analysis
4.3.1 Market Sizing (Actual & Forecasted)
4.3.2 Market Share by Insulin Type
4.3.3 Market Share by Segment
4.3.4 Market Share by Region

5. Insulin Delivery Devices
5.1 Overview
5.1.1 Vials & Syringes
5.1.2 Insulin Pens
5.1.3 Insulin Pumps
5.1.4 Insulin Jet Injectors
5.2 Market Analysis
5.2.1 Market Sizing (Actual & Forecasted)
5.2.2 Market Share by Devices
5.2.3 Market Share by End-User
5.2.4 Market Share by Region
5.2.5 Market Share by Nations

6. Insulin Delivery Devices - Market Segmentation
6.1 Vials and Syringes
6.1.1 Overview
6.1.2 Market Sizing (Actual & Forecasted)
6.2 Insulin Pens
6.2.1 Overview
6.2.2 Market Sizing (Actual & Forecasted)
6.2.3 Market Share by End-User
6.3 Insulin Pumps
6.3.1 Overview
6.3.2 Market Sizing (Actual & Forecasted)
6.3.3 Market Share by End User
6.4 Insulin Jet Injectors
6.4.1 Overview
6.4.2 Market Sizing (Actual & Forecasted)
6.5 Others

7. Regional Analysis
7.1 Europe
7.1.1 Overview
7.1.2 Market Sizing (Actual & Forecasted)
7.1.3 Market Share by Devices
7.1.4 Germany
7.1.4.1 Market Sizing (Actual & Forecasted)
7.1.4.2 Market Share by Device
7.1.5 France
7.1.5.1 Market Sizing (Actual & Forecasted)
7.1.5.2 Market Share by Devices
7.1.6 Italy
7.1.6.1 Market Sizing (Actual & Forecasted)
7.1.7 The UK
7.1.7.1 Market Sizing (Actual & Forecasted)
7.7.1.2 Market Share by Devices
7.2 North America and Caribbean
7.2.1 Overview
7.2.2 Market Sizing (Actual & Forecasted)
7.2.3 The US
7.2.3.1 Market Sizing (Actual & Forecasted)
7.2.3.2 Market Share by Product
7.3 Asia Pacific
7.3.1 Overview
7.3.2 Market Sizing (Actual & Forecasted)
7.3.3 China
7.3.3.1 Market Sizing (Actual & Forecasted)
7.3.4 Japan
7.3.4.1 Market Sizing (Actual & Forecasted)
7.3.4.2 Market Share by Devices
7.3.5 India
7.3.5.1 Market Sizing (Actual & Forecasted)

8. Pricing Analysis

9. Global Insulin Market Dynamics
9.1 Industry Trends & Developments
9.1.1 Approval of First Oral GLP-1
9.1.2 Advent of Reusable Smart Insulin Pens
9.1.3 Approval of First Artificial Pancreas System
9.1.4 Next-Generation Insulin Management System Platform
9.2 Growth Drivers
9.2.1 Prevalance of Diabetes
9.2.2 Rise in Geriatric Population
9.2.3 Growing Obese Population
9.2.4 Propagation of Diabetes Management Awareness
9.2.5 Government Impetus
9.3 Challenges
9.3.1 High Cost of Insulin Pumps
9.3.2 Insufficient Reimbursement
9.3.3 Stringent Regulatory Compliance

10. Competitive Landscape
10.1 Insulin Market
10.2 Insulin Delivery Devices
10.2.1 Insulin Delivery Devices Market
10.2.2 Insulin Pens Market
10.2.3 Insulin Pumps Market

11. Company Profiles
11.1 Novo Nordisk
11.2 Sanofi Aventis
11.3 Eli Lilly and Company
11.4 Merck & Co.
11.5 Beckton Dickinson

List of Tables and Figures
Figure 1: Research Methodology
Figure 2: Top ten countries/territories for Number of Adults with Diabetes (Million)
Figure 3: Global Diabetes Healthcare Expenditure and Treatment Cost per Patient, 2019 (US$ Billion)
Figure 4: Global Diabetes Care Market by Treatment Class, 2011-19 (US$ Millions)
Figure 5: Block Diagram Representation of Insulin Regulation in Body
Figure 6: Insulin Production and Action
Figure 7: Evolution of Insulin
Figure 8: Global Insulin Market Size by Value, 2014-25E (US$ Billions)
Table 1: Insulin and Diabetes Drugs Approved in the Period (2012-2019)
Figure 9: Global Insulin Market Share by Type (2019)
Table 2: Worldwide Sales of Various Types of Insulin, 2019 (US$ Billions)
Figure 10: Global Insulin Market (Volume) Share by Segment (2019)
Figure 11: Global Insulin Market (Volume) Share by Region (2019)
Table 3: Comparison of Various Insulin Delivery Methods
Figure 12: Global Insulin Delivery Devices Market Size by Value, 2014-25E (US$ Billions)
Figure 13: Global Insulin Delivery Devices Market Share by Product, 2014-25E (%)
Figure 14: Global Insulin Delivery Devices Market Share by End-User, 2016 & 2025E (US$ Million)
Figure 15: Global Insulin Delivery Devices Market Share by Region (2019)
Figure 16: Global Insulin Delivery Devices Market Share by Nations (2019)
Figure 17: Global Insulin Syringes Market Size by Value, 2014-25E (US$ Billions)
Figure 18: Global Insulin Injectors Market Size by Value, 2014-25E (US$ Billions)
Figure 19: Global Insulin Pens Market Size by Value, 2014-25E (US$ Billions)
Figure 20: Global Insulin Pens Market Share by End-User (2019)
Table 4: Top Insulin Pump Comparisons
Table 5: Comparison of Insulin Pumps and Insulin Pens
Figure 21: Global Insulin Pumps Market Size by Value, 2014-25E (US$ Billions)
(2019)
Figure 23: Global Insulin Jet Injectors Market Size by Value, 2014-25E (US$ Billions)
Table 6: Europe Diabetes Statistics
Figure 24: Europe - Insulin Market Size by Value, 2014-25E (US$ Billions)
Figure 25: Europe Insulin Delivery Devices Market Size by Value, 2014-25E (US$ Billions)
Figure 26: Europe Insulin Delivery Devices Market Share by Devices (2019)
Table 7: Germany Diabetes Statistics
Figure 27: Germany Insulin Delivery Devices Market Size by Value, 2017-25E (US$ Billions)
Figure 28: Germany Insulin Delivery Devices Market Share by Devices (2019)
Table 8: France Diabetes Statistics
Figure 29: France Insulin Delivery Devices Market Share by Devices (2019)
Figure 30: France Insulin Delivery Devices Market Share by Devices (2019)
Table 9: Italy Diabetes Statistics
Figure 31: Italy Insulin Delivery Devices Market Size by Value, 2017-25E (US$ Billions)
Table 10: The UK Diabetes Statistics
Figure 32: The UK Insulin Delivery Devices Market Size by Value, 2017-25E (US$ Billions)
Figure 33: The UK Insulin Delivery Devices Market Share by Devices (2019)
Table 11: North America Diabetes Statistics
Figure 34: North America - Insulin Market Size by Value, 2014-25E (US$ Billions)
Figure 35: North America - Insulin Delivery Devices Market Size by Value, 2017-25E (US$ Billions)
Table 12: The US Diabetes Statistics
Figure 36: The US - Insulin Market Size by Value, 2014-25E (US$ Billion)
Figure 37: The US Insulin Delivery Devices Market Size by Value, 2017-25E (US$ Billions)
Figure 38: The US Insulin Delivery Devices Market Share by Product, 2014-25E (%)
Table 13: Asia Pacific Diabetes Statistics
Figure 39: Asia Pacific - Insulin Market Size by Value, 2014-25E (US$ Billions)
Figure 30: Asia Pacific Insulin Delivery Devices Market Size by value, 2014-25E (US$ Billions)
Table 14: China Diabetes Statistics
Figure 31: China - Insulin Market Size by Value, 2014-25E (US$ Billion)
Figure 32: China Insulin Delivery Devices Market Size by Value, 2017-25E (US$ Billions)
Table 14: Japan Diabetes Statistics
Figure 33: Japan - Insulin Market Size by Value, 2014-25E (US$ Billion)
Figure 34: Japan Insulin Delivery Devices Market Size by Value, 2017-25E (US$ Billions)
Figure 35: Japan Insulin Delivery Devices Market Share by Devices (2019)
Table 15: India Diabetes Statistics
Figure 36: India Insulin Delivery Devices Market Size by Value, 2017-25E (US$ Billions)
Figure 37: India Insulin Delivery Devices Market Size by Value, 2017-25E (US$ Billions)
Table 16: Prices of Popular Insulins
Figure 38: Cost of Insulin, Jul’1996 - Jul’2019
Figure 39: Worldwide Insulin Cost Increment, 2005 vs. 2018
Figure 40: Worldwide Insulin Price Comparison, Cost per vial of Insulin (2019)
Figure 41: Intelligent Insulin Pens Connectivity Options
Figure 42: Illustration of Artificial Pancreas System
Figure 43: Next-Generation Insulin Management System Platform
Figure 44: Worldwide Diabetes Incidence by Region, 2015 & 2040E (Millions)
Figure 45: Prevalence of People with Diabetes by Age and Sex, 2018
Figure 46: Global Obese Population 2012-19 (Millions)
Table 17: Proportion of Undiagnosed Diabetic Population Aged (20-79 years), 2018
Table 18: Coverage of Popular Insulin Drug Brands
Figure 47: Global Diabetes Care Market (Value) Share by Competitors (2019)
Figure 48: Global Modern Insulin Volume Market Share by Competitors (2019)
Figure 49: Global Basal Insulin Market Share by Drug Brands (2019)
Figure 50: Global Rapid-Action Insulin Market Share by Drug Brands (2019)
Figure 51: Global Insulin Delivery Devices Market Share by Competitors (2019)
Figure 52: Global Insulin Pens Market Share by Competitors (2019)
Figure 53: Global Smart Insulin Pens Market Share by Competitors (2019)
Figure 54: Global Insulin Pumps Market Share by Companies (2019)
Figure 55: Global Disposable Insulin Pumps Market Share by Companies (2019)
Figure 56: Novo Nordisk Diabetes and Obesity Care Sales by Segment, FY2015-FY2019 (US$ Billion)
Table 19: Novo Nordisk - Diabetes R&D Pipeline
Figure 57: Novo Nordisk Insulin Pipeline
Figure 58: Novo Nordisk Net Sales, FY2015-FY2019 (US$ Billion)
Figure 59: Sanofi Aventis Revenue by Business Segment (FY2019)
Table 20: Sanofi Aventis Diabetes Pipeline
Figure 60: Sanofi Aventis Net Sales, FY2015-FY2019 (US$ Billion)
Figure 61: Eli Lilly and Company Revenue by Business Segment (FY2019)
Table 21: Eli Lilly and Company Diabetes Therapeutics
Table 22: Eli Lilly and Company Clinical Development Pipeline
Figure 62: Eli Lilly and Company Net Sales, FY2015-FY2019 (US$ Billion)
Table 23: Merck & Co. Product Pipeline
Figure 63: Merck & Co. Revenue by Business Segment (FY2019)
Figure 64: Merck & Co. Net Sales, FY2015-FY2019 (US$ Billion)
Table 24: Beckton Dickinson Product Pipeline
Figure 65: Beckton Dickinson Revenue by Business Segment (FY2019)
Figure 66: Beckton Dickinson Net Sales, FY2015-FY2019 (US$ Billions)
Note: Product cover images may vary from those shown
3 of 3
  • Novo Nordisk
  • Sanofi Aventis
  • Eli Lilly & Company
  • Merck & Co.
  • Beckton Dickinson
Note: Product cover images may vary from those shown
Adroll
adroll